March 17, 2020
Interim Study Results Presented for Artio Medical’s Endura Embolization System
March 17, 2020—Artio Medical announced that interim nonclinical study results for the company’s Endura embolization system were presented by Blaise Baxter, MD, at the ABC-WIN (Anatomy-Biology-Clinical Correlations–Working Group in Interventional Neuroradiology) seminar held January 12–17 in Val d'Isere, France.
The data demonstrated that use of the Endura device in bifurcation aneurysms can result in greater aneurysm occlusion and lower coil prolapse into parent arteries when compared with commercially available coil-only treatments, stated the company.
Funded by a phase 1 Small Business Innovation Research grant from the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, the study compared the efficacy of the Endura device to coil-only treatments for the occlusion of aneurysms in a challenging model of terminal bifurcation aneurysms.
Artio Medical stated that the Endura system is designed for placement within the aneurysm sac to provide immediate aneurysm occlusion. It has three components: a detachable polymer balloon device (the Endura embolization accessory device), Endura aneurysm coils, and Endura balloon coils. These components are designed to work together to cover the aneurysm neck, frame and fill the aneurysm sac, and provide immediate aneurysm occlusion while reducing the risk of coil prolapse into the parent vessel.
The company advised that the Endura embolization system’s combination of coils and a balloon has the potential to provide immediate cerebral aneurysm occlusion, reduce the risk of coil prolapse, and promote endothelialization of the aneurysm neck by presenting a flat, solid surface at the aneurysm neck.
Dr. Baxter, a neurovascular and peripheral interventional radiologist, commented in the company’s press release, “The Endura embolization device covers the aneurysm neck and provides a platform to embolize the remainder of the aneurysm sac. I am pleased to be the first to present the Endura technology to my peers. It is exciting to have this promising option on the horizon, and I believe it has the potential to significantly improve outcomes for patients with cerebral aneurysms.”